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The analysis of the genomic distribution of viral vector genomic integration sites is a key step in hematopoietic stem
cell-based gene therapy applications, allowing to assess both the safety and the efficacy of the treatment and to study
the basic aspects of hematopoiesis and stem cell biology. Identifying vector integration sites requires ad-hoc
bioinformatics tools with stringent requirements in terms of computational efficiency, flexibility, and usability. We
developed VISPA (Vector Integration Site Parallel Analysis), a pipeline for automated integration site identification and
annotation based on a distributed environment with a simple Galaxy web interface. VISPA was successfully used for the
bioinformatics analysis of the follow-up of two lentiviral vector-based hematopoietic stem-cell gene therapy clinical
trials. Our pipeline provides a reliable and efficient tool to assess the safety and efficacy of integrating vectors in clinical
settings.Background
Viral vectors, due to their ability to permanently integrate
in a target genome, are used to achieve the stable genetic
modification of therapeutically relevant cells and their
progeny. In particular, γ-retroviral (γ-RVs) and lentiviral
(LVs) vectors are the preferred choice for hematopoietic
stem/progenitor cell (HSPC) gene therapy (GT) applica-
tions, having proved their efficacy in several preclinical
assays and clinical trials for inherited monogenic disorders
[1-4]. Since γ-RVs and LVs integrate in the cellular gen-
ome in a semi-random fashion [5-8], in a population of
vector marked cells each clone and its progeny harbor an
integrated vector in a unique genomic position that can
be used as a distinctive genetic identifier.
Studies aimed at investigating the genomic distribution
of integrating vectors in blood cells of GT patients are
fundamental to assess the safety and efficacy of the
therapy. Indeed, in some cases HSPC-GT was associated
to the potential emergence of severe adverse effects that
involve the perturbation of the expression of genes in* Correspondence: montini.eugenio@hsr.it
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unless otherwise stated.the proximity of the vector’s integration site (IS), a
phenomenon known as insertional mutagenesis (IM)
[1,9-12]. The identification of ISs on leukemic cells from
GT patients and preclinical models allowed identifying
the causes of IM and tracking the evolution of the
malignant clone over time [11-16]. State-of-the-art
strategies for the identification of ISs start with the
amplification, via polymerase chain reaction (PCR), of
the DNA portion that contains part of the proviral gen-
ome and of the flanking cellular genome. PCR products
are then sequenced and mapped to the reference host
genome to determine the genomic coordinates of the
ISs. More recently, next generation sequencing (NGS)
approaches have greatly enhanced the power of IS ana-
lysis, allowing to recognize clonal expansions caused by
in vivo selection of gain-of-function insertional mutants
even before they progress to overt malignancy. More-
over, IS analysis is useful to address clonal diversity dur-
ing hematopoietic reconstitution and the levels of HSPC
marking and activity after transplant, thus providing
readouts for efficacy. For these reasons, over the past
years there has been a constant increase in the amount
of sequencing and mapping of vector/genomic DNA
junctions, as well as an increasing diversification ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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itoring. However, despite the advances brought forth by
NGS approaches and the higher level of detail provided by
the additional cell types and time points, there is still a
clear lack of computational tools that offer both a level of
performance capable of dealing with the huge amount of
data generated by sequencing platforms and sufficient
usability to make them accessible to investigators with
varying degrees of technological expertise.
Here we describe the design and implementation of
VISPA (Vector Integration Sites Parallel Analysis), a bio-
informatics pipeline for the identification of ISs built on a
scalable infrastructure with a simple graphical user inter-
face (GUI) based on the popular Galaxy framework [17].
VISPA has been successfully applied in several studies on
mouse and human genome [3,4,18,19]. In this work we
describe its performance on human IS datasets. This ana-
lysis allowed us to highlight critical points negatively
impacting the efficiency of IS retrieval and mapping and
provided hints to improve the whole process. VISPA is
available at [20].
Implementation
VISPA has been specifically designed to analyze DNA
fragments generated by linear-amplification (LAM) medi-
ated PCR [21], a technique used to retrieve and amplify
DNA fragments containing the junctions between the
integrated proviral and the cellular genome. Due to its
high sensitivity and accuracy, LAM-PCR is the current
standard for preclinical and clinical GT studies. The DNA
fragments generated with this method range from 100 to
1,000 bp in length, and contain the proviral long terminal
repeat (LTR), the flanking genomic DNA and a linker
cassette (LC). LAM-PCR products are then reamplified
by PCR with fusion primers containing a specific 6-
nucleotide sequence (barcode) that acts as a tag to allow
sample recognition after multiplexing. Barcoded frag-
ments are then purified, quantified, grouped into pools
and sequenced with either Roche 454 or Illumina MiSeq
platforms. As a result of this procedure, the sequencing
reads contain not only the genomic fragment needed for
IS identification, but also viral and artificial sequences that
must be trimmed out before alignment to the reference
genome. Finally, sequencing reads must be processed by a
bioinformatics pipeline that yields the final list of anno-
tated ISs (Figure 1).
Bioinformatics pipeline
The bioinformatics pipeline (Figure 1C) consists of several
sequential steps that lead from raw sequencing reads to
the annotated ISs. The first step converts reads from the
output format of the sequencer to the FASTA format;
sequencing data are then parsed to identify barcodes and
perform demultiplexing (that is, write a separate FASTAfile for each barcode); the LTR and LC sequences are sub-
sequently removed from each read to isolate genomic
fragments; in the next step, reads are mapped to the refer-
ence genome and several filters are applied to ensure
unambiguous alignment; after that, ISs that fall in the
same 3 bp window are merged together; finally, all ISs are
annotated by listing nearby genomic features (for example,
genes). In a subsequent postprocessing step, each IS is
associated to the LAM-PCR sample from which it was
originally derived, allowing its assignment to a source (for
example, peripheral blood, bone marrow and so on), cell
type (for example, CD4+ T cell, CD19+ B cell, and so on),
and time point after treatment.
Format conversion
In the data extraction step, standard flowgram format
(SFF, for the Roche 454) or FASTQ (for the Illumina
MiSeq) files are converted to the FASTA format with a
wrapper for the sff_extract program [22]. In the course of
our experiments, before running the pipeline, we also had
to convert paired-end FASTQ files from the Illumina
MiSeq to single-strand. In the case of Illumina paired-end
data, before running the pipeline, we converted the reads
to single-strand as follows: for each read, we determined
the LTR’s orientation to identify the starting nucleotide;
then, for overlapping reads, we merged the pair, while for
non-overlapping reads we only kept the one that con-
tained the LTR, which allows identifying the IS.
Demultiplexing
To avoid NGS capacity underutilization, several samples
are often sequenced at the same time, a technique called
multiplexing. To enable the redistribution of output
reads into separate groups (demultiplexing), samples are
tagged with individual ‘barcode’ sequences. Our demulti-
plexing tool, implemented in Python, identifies barcodes
and uses them to demultiplex sequence data, producing
a separate FASTA file for each barcode. To demultiplex
sequencing data, we developed a simple exact string pat-
tern matching: the input is a list of barcode sequences
that will be searched for at the beginning of each read,
while the output consists of a separate FASTA file for
each barcode (reads that do not contain any known tag
are discarded). To avoid biases due to the possible mis-
classification of similar sequences, no mismatches are
tolerated in this phase.
Trimming
Sequencing reads produced in the context of GT contain
both viral fragments and artificial sequences introduced as
a side effect of the procedure. In the trimming step, these
sequences (the LTR and LC) are identified and removed
to isolate the genomic fragments. Our implementation
consists of a Python program that integrates the BLAST
Figure 1 IS analysis procedure for the Roche 454 sequencing platform. (A) DNA fragments containing the vector-cellular genome junctions
are retrieved and amplified from vector marked genomic DNA by LAM-PCR. (B) LAM-PCR products are processed by the NGS platform, yielding
sequencing reads that have to be processed in silico. (C) Bioinformatics pipeline, from FASTA extraction to IS identification and annotation.
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around the NCBI C++ Toolkit [25]. The program searches
for a subsequence consisting of the last 63 nucleotides of
the LTR, imposing an alignment homology of at least 89%
and a perfect match on the last 3 bases. If the LTR is
found, it is removed from the read and the resulting se-
quence is kept for further analysis to avoid mapping aspe-
cific amplification products. All reads that do not contain
the LTR are instead discarded. Reads that pass the above
filter are searched for the presence of the LC, which is also
trimmed out from the read. Note that the absence of the
LC does not imply that the read is the product of an aspe-
cific amplification reaction: thus, reads that do not contain
the LC are not eliminated from subsequent analysis, in
contrast with what happens to the LTR. Finally, all
trimmed sequences less than 20 bp long are discarded. As
shown in the Results section, this setup results in a highly
accurate identification of the junction point between the
LTR and the genomic sequence, which represents the IS
itself. Hereinafter, we will refer to the set of trimmed reads
as T.
Alignment and filtering
To find out where in the host DNA the viral vector has
integrated itself, sequencing reads must be mapped to a
reference genome. Our implementation consists of a
distributed version of BLAST with custom filters: for
each read in T, BLAST outputs a series of hits corre-
sponding to matching genomic regions, supported by
statistics such as alignment score, starting position, and
so on. Since an IS is defined as the junction between the
vector and the host genome, the part of the sequence
flanking the viral LTR must be identified as accurately
as possible, and reads must be univocally mapped to the
reference genome: these requirements are addressed by
a series of filtering procedures described in the rest of
this section.
In our experiments, to avoid mapping errors, we dis-
carded all hits with an identity score lower than 95% as
well as those with a starting alignment position beyond
the third base. The rationale behind the latter filter is
justified by PCR biases and biological changes for which
the position of a given IS can oscillate in a range of +/-
3 bases with respect to aligned reads [26,27]. Although
these are the recommended choices, both the minimum
identity score and the maximum starting position are
exposed as configurable parameters to the user. In the
following text, reads successfully mapped to the refer-
ence genome according to the above rules will be de-
noted as M, while discarded reads will be referred to as
N, so that |T| = |M| + |N|.
In order to univocally associate a genomic region to
each IS, sequencing reads that map equally well to mul-
tiple regions of the genome must be discarded: thus, readsfrom M are subject to further filtering in order to isolate
unambiguous alignments. We here introduce the hom-
ology score hs that, for every mapping m of a given read i,
represents the percentage of aligned bases with respect to
the length of the read:
hsim ¼ 100  qs−qej jim=li
where qs and qe are, respectively, the starting and end-
ing positions of the query (input read) in the alignment
as reported by BLAST, and l is the length of the read. A
read is classified as unambiguously aligned (U set) if its
best hit in terms of alignment score as has significantly
better values of both as and hs than the second best hit;
otherwise, it is discarded as ambiguously aligned (A set,
so that |T| = |U| + |A| + |N|). More specifically:
1. All hits for a given read are sorted in decreasing as
order as(1), as(2), … as(|M|);
2. If both |as(2) - as(1)| > ast and |hs(2) - hs(1)| > hst,
where ast and hst are predefined thresholds, the
alignment is classified as unambiguous. In our exper-
iments, we set ast and hst, respectively, to 15 and 20,
after a parameter tuning phase performed on a con-
trolled murine dataset.
Since the two LTRs present in the integrated proviral
form of LV are direct repeats, LAM PCR amplification
also generates a product containing part of the lentiviral
genome downstream the 5’ LTR. To detect viral se-
quences, we added a ‘dummy chromosome’ to the refer-
ence genome, corresponding to the vector genome: in
this way, NGS reads are also aligned to the vector
genome, and reads that map to both genomes are shown
in the BLAST output, enabling their removal from sub-
sequent steps. Finally, we applied an alignment quality
filter to the reads in U, discarding all alignments with a
BLAST identity score lower than 95% and hs less than
80%. The set of reads that pass this filter will be sub-
sequently denoted as R.Integration site merging
Due to the possible presence of technical biases, we
applied a previously validated [6,26,27] 3 bp tolerance
window on the genomic position of the IS (that is, the
starting point of the alignment): all reads in R that lie in
the same window are merged into a single locus, repre-
sented by the first position in the window itself. This is
achieved by simply sorting reads by their starting
position on each reference chromosome and running a
sliding window [28] on the sorted list. We will refer to
the resulting set of distinct IS as L.
Figure 2 Simplified architecture of the distributed alignment,
filtering tool, control, and flow in the distributed
implementation. The MapReduce workers repeatedly call BLAST on
each query sequence in the input subset assigned to it by the
Hadoop framework. Each stream of BLAST results is then filtered
according to the specified rules: if there are no results left at this
point, the read is discarded (N set, no-hit); otherwise, remaining hits
are classified as either ambiguous (A set, repeats) or unambiguous
(U set). Finally, a local output collector opens all MapReduce output
files (one per worker) and merges them into three new files, one for
each category. In the course of the data analysis performed for our
clinical trials, the alignment and filtering step has been run on up to
240 CPU cores simultaneously.
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The final step is the annotation of ISs, where each site is
associated to nearby genomic features such as genes,
miRNAs, and so on. We developed our own annotation
tool that takes as input two main parameters:
1. The L set, with each IS characterized by (at least)
its genomic location, that is, chromosome name
and position within the chromosome;
2. A browser extensible data (BED) file [29] containing
a list of genomic features, each characterized by
(at least) its name, the name of the chromosome on
which it is found, its starting and ending position on
the chromosome itself, and its orientation (plus or
minus strand). Examples of gene annotation BED
files are available in our Galaxy front-end in the
shared library area.
For each IS, the program finds the closest feature(s)
among those listed in the annotation file and, for each fea-
ture, outputs the following information: the (chromosome,
position) tuple that identifies the IS; the name and strand
of the feature as they appear in the BED file; the feature’s
starting and ending position; the distance of the IS from
the feature’s transcription start site (TSS); the relative
position of the IS with respect to the feature (upstream,
downstream or in-gene); the integration percentage for in-
gene integrations (from 0% when the IS coincides with the
TSS to 100% when the IS lies at the opposite end of the
feature).
Development
All tools in the pipeline were developed in Python, used
either exclusively or as a wrapper around foreign libraries
and external executable. For each tool, we built a Galaxy
[17] front-end that allows interacting with it through an
intuitive interface based on text boxes, drop-down menus,
and so on.
With the exception of the alignment and filtering step,
all programs have been implemented as ordinary execut-
able scripts depending on a common software library. The
alignment and filtering step, on the other hand, posed a
significantly greater challenge in terms of running time
and scalability. In our experiments, nearly 14 million input
reads had to be mapped to the whole human reference
genome: a task that, on a single processor, would have
taken an amount of time incompatible with the turn-
around requirements of the clinical trials. Since the map-
ping job is easily parallelizable on the set of input
sequences and a near-linear speedup can be achieved by
partitioning the input dataset set into a number of subsets
equal to that of available CPU cores (in the ideal case of
perfect load balancing), we implemented the tool as
an application for Apache Hadoop [30], a distributedcomputing framework that handles dataset partitioning,
load balancing, and re-execution of failed task trans-
parently according to the MapReduce paradigm [31].
While Hadoop’s native API is in Java, to keep the code
base consistent with the rest of the pipeline we developed
the application with Pydoop [32], a Python API for
Hadoop developed at CRS4 (Figure 2).
From an architectural standpoint, the pipeline is struc-
tured as follows:
 A graphical web-based user interface built with
Galaxy;
 A job dispatcher and workflow manager, also based
upon Galaxy;
 A high-performance computer cluster where appli-
cations are actually run.
The Galaxy server runs on a node enabled for job sub-
mission on the cluster’s resource manager (RM). While
most pipeline tools are executed on single CPU cores
assigned to them by the RM, the distributed alignment
and filtering step runs concurrently on cluster sub-
sections managed by Hadoop (Figure 3).
Results and discussion
We performed a series of tests to evaluate VISPA’s reli-
ability in IS identification as well as its performance in
the analysis of large datasets. We generated an in silico
dataset of IS and used it to test our tool and other pub-
licly available software for IS analysis, as described in the
next subsection. In the following subsection, we charac-
terized the computational performances of our tool by
analyzing large datasets of real IS previously obtained
from two GT studies [3,4].
Figure 3 Schematic representation of the pipeline’s architecture. Interaction with the system happens through a Galaxy-based GUI: after
logging in to the web site, the user is able to upload data and customize the various parameters using a dedicated subsection of the Galaxy tool
panel (1). Although each pipeline step can be run as a stand-alone tool, Galaxy also allows to combine them in a single workflow, thus enabling
the automation of the entire process. When the user submits a job, Galaxy transfers all parameters chosen via the GUI to a driver script (2), which
schedules the actual computation on the computing cluster (3). In the case of the alignment and filtering step, actual processing is further
delegated to Hadoop (4), while the driver script acts as a final output collector. Finally, job output is returned to the graphical front end (5) that
presents final results to the user (6).
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We assessed the reliability of our tool and other available
software (Mavric [33], SeqMap [34] and QuickMap [35]),
on an in silico dataset of 455 human sequences that simu-
late ISs with pre-determined genomic coordinates, charac-
terized by different length, sequence complexity and
mappability (see Additional files 1 and 2). We analyzed
this dataset with VISPA and the other selected tools com-
paring results with the expected outcome (see strategy in
Figure 4A). We exploited two of the most recent next gen-
eration sequencing (NGS) aligners, BWA [36] and GEM
[37], as reference to verify the mappability of the test
sequences on the target genome, thus allowing the classifi-
cation of each sequence as a repeat or not. The classifica-
tion of each sequence as repeat or unique position in the
genome can be computed using a ratio between the alter-
native/suboptimal alignment score and the optimal one
(for simplicity here called homology percentage or ratio).
Once an appropriate threshold has been set for thehomology ratio, input ISs are either accepted as un-
ambiguously mapped or rejected as repeats. Figure 4B
shows how classification results change as the homology
percentage threshold varies between 20% and 100%, thus
simulating a varying degree of stringency. For instance, in
our synthetic dataset, a 90% threshold (that means that
two alignments are considered repeats if and only if
the ratio the alternative alignment and the optimal
one is ≥ 0.9) leads to 449 accepted and six rejected ISs. For
all four tools, sequences passing homology filtering were
subsequently labeled as discarded (not identified as a
mapped IS), correctly matched (if the chromosome and
genomic position are correct within +/- 2 bp), or mis-
matched (wrong chromosome and/or genomic position). In
this framework we are able to use standard statistical mea-
sures to evaluate precision, sensitivity, specificity, accuracy,
and false discovery rate (FDR) by accounting for what we
expect to observe in our data (given an homology percent-
age ratio, or testing for an increasing value of homology
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Figure 4 Reliability evaluation of VISPA and other IS analysis tools. (A) Overall strategy for reliability assessment, from the generation of the
synthetic dataset to the final results. (B) Number of sequences classified as ISs or repeats for increasing homology percentage thresholds. (C-G)
Precision, FDR, sensitivity, accuracy, and specificity of all tested tools for increasing homology percentage thresholds.
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http://genomemedicine.com/content/6/9/67ratio) versus what we obtained from the tools. True
positives (TP) are actual ISs that are identified as such
by a tool; false positives (FP) are actual repeats that are
identified as ISs and mismatched ISs; false negatives
(FN) are actual ISs identified as repeats; true negatives
(TN) are actual repeats (discarded sequences) that are
identified as such.
Since the number of classified IS and repeats did not
changed up to the homology percentage value of 50
(Figure 4B), we compared statistical results of the IS
analysis tools in the neighborhood interval of 70%. In
terms of precision (Figure 4C) and FDR (Figure 4D),
VISPA and SeqMap resulted the best tools. In terms of
sensitivity (Figure 4E), VISPA and QuickMap performed
similarly (0.94 and 0.95, respectively) in top ranking po-
sitions, whereas MAVRIC and SeqMap achieved lower
values (less than 0.8); similar results were obtained for
the accuracy (Figure 4F). For the specificity (Figure 4G)
we observed for VISPA an increasing trend as the
homology percentage increased, reaching 1 at 90%
homology; only MAVRIC showed a similar trend, while
SeqMap and QuickMap presented an opposite behavior,
with the latter reaching 0 at 80% homology. For what
concerns the analysis of mismatched IS, MAVRIC
yielded an amount of 50 mismatched IS clustered in a
distance between 100 and 500 bp from the reference IS
position (Additional file 3A; in contrast, SeqMap pre-
sented only 1 mismatched IS, located in a different
chromosome; finally, QuickMap yielded 18 mismatched
ISs, the majority of them (12) within 10 bp from the
reference position (Additional file 3B).
Computational performance of VISPA on IS datasets from
GT studies
We analyzed the performance of VISPA in the context of
the analysis of 19,306,267 raw sequence reads obtained in
two GT previous studies [3,4]. After quality control and
barcode filtering, 18,874,038 total input reads were
selected, 13,786,956 of which contained a valid LTR
sequence (the previously introduced T set); these reads
were subsequently aligned to the human reference
genome (build hg19/GRCh37, February 2009) yielding
12,717,773 mappings (corresponding to the M set) and
1,069,183 unmatched reads (the N set); after the filtering
step, the M set was further split into the A and U subsets,
with a total amount of, respectively, 2,572,931 and
6,035,527 reads. LV detected reads were 4,109,315. The
alignment quality filter discarded 541,122 reads, leaving a
total amount of 5,494,405 redundant ISs (the R set). After
merging ISs according to the sliding window method de-
scribed above, the resulting 71,359 distinct ISs (the L set)
were finally annotated with nearby genomic features.
From this analysis we found that for all patients, despite
the large amount of sequences generated by the 454-Rocheor MiSeq Illumina platforms, after the sequential filtering
steps applied by our pipeline, the number of sequencing
reads univocally mapped on the genome was progressively
reduced to 30% of the initial number of sequencing reads.
Several reasons, although to a different extent, concurred
to this strong reduction.
The percentage of reads with correct barcodes ranged
from 96.61% to 99.23% of the total (Figure 5A). On the
other hand, about 30% of the sequencing reads was ex-
cluded after trimming (Figure 5B) due to the absence of
a valid LTR (12% on average) or because they were too
short to be mapped on the reference genome (15% on
average). The decrease in number of reads associated to
the first three filtering steps was comparable in all pa-
tients (Figure 5A, B). As shown in Figure 5C, the trim-
ming step modifies the distribution of the length of
sequencing reads by introducing a shift towards smaller
sizes and a slight change in its profile. After the align-
ment to the reference genome (Figure 5D) about 40% of
the initial reads was excluded from further analysis be-
cause: (1) lacking a valid match on the reference gen-
ome (6% on average); or (2) because these reads were
vector-only sequences (21% on average); or (3) repetitive
elements that could not be univocally mapped to the
reference genome (13% on average). Reads left after
quality-based filtering (the R dataset) were, on average,
90.87% of U reads, with a standard deviation of less than
1%. The sequence length distribution profile of the uni-
vocally mapped reads (the R dataset) was similar for all
patients of both clinical studies (Figure 6A). Finally by
applying the sliding window approach described above,
we identified all IS reads that fall in the same 3 bp inter-
val as belonging to the same integration event (the IS
merging step), the number of such reads can be seen as
a measure of the ‘signal power’ of the integration
(Figure 6B). To evaluate the precision of this approach,
we computed the percentage of IS positions (starting
covered bases) hit by an IS read within each window: as
shown in Figure 6B, over 60% of IS bases fall in the first
position (blue bar), while for other bases the percentage
decreases as the distance from the IS increases.
In summary, we found that four major steps account for
the observed strong reduction in the amount of sequence
reads: (1) LTR recognition; (2) short sequence reads; (3)
vector-only sequences; (4) repetitive elements. To increase
the yield of sequences with a recognizable LTR, further
optimization of the parameters for its recognition could
be adopted, carefully evaluating the possible impact on
the alignment quality and errors. To significantly reduce
the number of short length reads, optimization of the wet
procedures could be required, such as developing other
LAM-PCR protocols optimized for the amplification of
long products as well as the use of sequencing technologies
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Figure 5 Pipeline results for the MLD and WAS clinical trials. (A) Histogram plot of sequence reads for each patient showing the decrease in
absolute number of reads after the demultiplexing and trimming steps. (B) Bar plot of the relative percentage of raw reads passing the trimming
step (in green) and filtered reads by length (blue bar) or invalid LTR reads (red bar) for each patient. (C) Effect on the frequency distribution of
the length of raw reads after trimming for two datasets obtained from two GT patients (MLD01 and WAS1001). (D) Bar plot of the relative
percentage of aligned reads for each patient: the input sequences are the trimmed reads, whereas the resulting subsets from the alignment step
are LV, U, A, and N.
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Similarly, to reduce vector-only sequences, further techno-
logical improvements should be adopted. In particular, the
use of novel oligonucleotides for LAM-PCR amplification
annealing in non-repeated portions of the HIV genome
(thus avoiding the LTR) could drastically reduce or com-
pletely eliminate the presence of such non-informative
contaminant.
The issue of the presence of repetitive sequences that can-
not be mapped univocally to the reference genome is more
complex to solve but it would lead to a major improvement
of IS analysis procedures. Many of the analyses take into ac-
count the number of univocally mapped integration sites as
surrogate markers of clonality, including the tracking of
HSPC reconstitution and differentiation to estimate thepolyclonal hematopoietic repertoire in terms of population
diversity, as well as the number of active stem cells that
reconstituted the hematopoietic system. Therefore the
lack of precise information regarding the number of cell
clones that harbor integrations in repetitive regions could
have a detrimental impact on the overall picture of these
analyses. To solve this issue, novel PCR techniques that
increase the length of the sequence reads may be devel-
oped, thus increasing the mappability of PCR sequenced
products [8].
Conclusions
IS analysis is an essential step for assessing the safety
and efficacy of molecular therapies that use genetically-
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Figure 6 IS reads and loci analysis. (A) Distribution of trimmed IS reads for all patients in the MLD and WAS clinical trials. (B) Histogram plot of
IS identification for each patient: values are in percentage and represent the amounts of covered bases within the 3 bp range for each IS.
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analyses should preferably be performed on different
hematopoietic cell lineages that are purified and isolated
from the bone marrow and/or peripheral blood of GT
patients at different time points after transplantation.
VISPA was extensively used to monitor lentiviral inte-
grations in two clinical studies for the treatment of MLD
and WAS, enabling to efficiently extract IS information
from a large number of samples (N > 1,400) and sequen-
cing reads (N = approximately 20 × 10e6 reads) and to
verify the safety and efficacy of the treatments in various
aspects [3,4]. For the first time, we were able to observe
in vivo molecular patterns of human stem cell differenti-
ation and proliferation, opening new perspectives to
understand cell dynamics through population studies.
Moreover, even if IS analysis has not been fully stan-
dardized yet, drug administration agencies require to
perform IS analysis both in preclinical experimentations
and GT clinical trials to identify potential insertional
mutagenesis events. The emerging interest of the scien-
tific community on these studies highlights the great po-
tential of IS analysis and, consequently, of tools capable
of efficiently and reliably perform the associated compu-
tational steps such as the one presented here. Hence,
this further increases the importance of bioinformatics
tools such as VISPA, designed not only for accuracy and
efficiency, but also for usability by researchers without
higher level of informatics expertise.
Availability and requirements
 Project name: VISPA
 Project home page: https://github.com/crs4/vispa Operating system(s): Unix
 Programming language: Python
 Other requirements: Galaxy, Hadoop
 License: GNU GPLv3
 Any restrictions to use by non-academics:
commercial use is permitted, see the GPLv3 for
requirements
Additional files
Additional file 1: Generation of the test set and accuracy
evaluation setup. This document provides in-depth details on the
generation of the in silico dataset, and describes the experimental setup
used to assess the accuracy of VISPA and other three IS analysis tools
(MAVRIC, SeqMap and QuickMap). See http://genomemedicine.com/
content/supplementary/s13073-014-0067-5-s1.pdf.
Additional file 2: In silico dataset sequences and accuracy
assessment results. This is a Microsoft Excel file with two tabs, ‘FASTA
formatted sequences’ and ‘comparison’: the former contains the 455
sequences that make up the synthetic dataset in FASTA format, while the
latter provides detailed information and experimental results for each
sequence. Specifically, the ‘INPUT’ column group contains sequence
annotation; the ‘BWA’ and ‘GEM’ column groups list results for each
aligner; in the remaining columns, results are provided for VISPA and the
other three tested tools. See http://genomemedicine.com/content/
supplementary/s13073-014-0067-5-s2.xlsx.
Additional file 3: Analysis of mismatched IS. (A) Box plot of the
distances, in terms of genomic position (bp), between each mismatched
IS and the reference IS, for MAVRIC, SeqMap, and QuickMap. (B) Total
number of mismatched ISs for different bp intervals. See http://
genomemedicine.com/content/supplementary/s13073-014-0067-5-s3.pdf.
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API: Application programming interface; FDR: False discovery rate; GT: Gene
therapy; GUI: Graphical user interface; HSPC: Hematopoietic stem/progenitor
cell; IS: Integration site; LAM-PCR: Linear amplification mediated polymerase
chain reaction; LV: Lentiviral vector; MLD: Metachromatic leukodystrophy;
NGS: Next-generation sequencing; WAS: Wiskott-Aldrich syndrome; γ-RV:
γ-retroviral vector.
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